What’s New in Alzheimer’s Drugs? FDA-Approved Treatments to Know
Recent FDA approvals have changed the conversation around dementia care by adding treatments that aim to slow part of the disease process, not just manage symptoms. Understanding who these drugs are for, how they work, and what practical limits remain can help patients and families make more informed decisions.
Care for memory loss is changing in a meaningful way. For many years, approved medicines mainly focused on easing symptoms such as forgetfulness, confusion, or day-to-day functional decline. Newer treatments have introduced a different approach: targeting amyloid, a protein linked to Alzheimer’s disease in the brain. That shift does not mean a cure has arrived, and it does not make every patient a candidate. It does mean that doctors, patients, and families now have more complex choices to weigh, including benefits, risks, testing requirements, monitoring, and cost.
New FDA-Approved Drugs for Alzheimer’s Disease
The newest FDA-approved medicines drawing the most attention are lecanemab, sold as Leqembi, and donanemab, sold as Kisunla. Both are monoclonal antibodies designed to reduce amyloid plaques in the brain. Unlike older Alzheimer’s drugs, these treatments are intended for people in the early symptomatic stages, such as mild cognitive impairment due to Alzheimer’s disease or mild dementia, and they generally require confirmation that amyloid is present.
Older approved medicines still matter. Drugs such as donepezil, rivastigmine, galantamine, and memantine remain part of standard treatment because they can help some people with symptoms, even though they do not remove amyloid. In practice, the newer drugs and the older symptom-focused drugs may be discussed together, depending on disease stage, overall health, and the goals of care.
What Makes These New Drugs Different?
The main difference is that the newer medicines are considered disease-modifying treatments, while the older group is mainly symptomatic. Symptomatic drugs may support attention, memory, or daily function for a period of time, but they do not directly target one of the biological hallmarks of Alzheimer’s disease. Lecanemab and donanemab were developed to lower amyloid burden, which may modestly slow cognitive and functional decline in some patients.
That difference also brings added complexity. These drugs are not used broadly across every stage of dementia, and they require closer monitoring. Patients may need amyloid testing through PET imaging or cerebrospinal fluid analysis before treatment starts. Regular MRI scans are also important because of a known side effect called ARIA, which can involve brain swelling or small areas of bleeding. Risk varies, and some people, including certain APOE ε4 carriers, may face higher chances of these complications.
Real-world decisions often come down to more than medical science alone. Annual list prices for the newer infused drugs have been reported in the tens of thousands of dollars, while older generic medicines are usually far less expensive per month. On top of the drug price, patients may face costs tied to infusions, brain imaging, specialist visits, lab work, and diagnostic testing. Insurance coverage, infusion setting, and region can all affect out-of-pocket spending, so any estimate should be treated as a snapshot rather than a fixed number.
| Product/Service Name | Provider | Key Features | Cost Estimation |
|---|---|---|---|
| Leqembi | Eisai and Biogen | Anti-amyloid antibody for early symptomatic disease with confirmed amyloid; IV treatment with MRI monitoring | Annual list price has been reported around $26,500, excluding related testing and infusion costs |
| Kisunla | Eli Lilly and Company | Anti-amyloid antibody for early symptomatic disease with confirmed amyloid; IV treatment with MRI monitoring | Annual list price has been reported around $32,000, excluding related testing and infusion costs |
| Donepezil | Generic; brand history includes Aricept | Symptom-focused treatment used across several stages in appropriate patients | Often much lower than newer infused drugs; generic cash and insurance prices vary widely |
| Memantine | Generic; brand history includes Namenda | Symptom-focused treatment often used in moderate to severe stages or in combination plans | Usually lower-cost than newer infused drugs, but exact pricing depends on pharmacy and coverage |
Prices, rates, or cost estimates mentioned in this article are based on the latest available information but may change over time. Independent research is advised before making financial decisions.
What Patients and Families Should Know
The most important practical point is that not every person with dementia will qualify for these newer therapies. They are generally meant for early Alzheimer’s disease with confirmed amyloid, not for advanced stages or for memory problems caused by other conditions. That means evaluation is a key part of treatment planning. Doctors may review cognitive testing, brain imaging, medical history, medications, bleeding risk, and whether a patient can reliably attend infusions and follow-up scans.
Families should also understand what these drugs can and cannot do. Current evidence suggests they may slow decline for some patients, but they do not restore lost memory, reverse established damage, or guarantee the same benefit for everyone. Decisions often involve balancing modest clinical benefit against treatment burden, travel, monitoring, possible side effects, and financial impact. This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.
The biggest change in the field is not simply that there are new names on a medication list. It is that Alzheimer’s treatment is moving toward earlier diagnosis, biological testing, and more individualized discussions about risk and benefit. Older drugs still have a role, while newer FDA-approved options have expanded what treatment can mean for some people. For patients and families, the landscape is more hopeful in some respects, but also more detailed and demanding than before.
